ADA: Inhaled Insulin Promising for Type 1 Diabetes

THURSDAY, June 27, 2024 – Recent research highlights the potential advantages of inhaled insulin for adults with type 1 diabetes, showing substantial improvements in hemoglobin A1c (HbA1c) levels over a period of 16 weeks compared to traditional care methods. This study was unveiled at the annual meeting of the American Diabetes Association, which took place from June 21 to 24 in Orlando, Florida.

Led by Dr. Irl B. Hirsch from the University of Washington in Seattle, the study involved a randomized trial that examined the effectiveness of a combination of an inhaled insulin regimen (Afrezza) and degludec insulin (Tresiba) against the usual care provided for type 1 diabetes patients. The trial included participants treated at 19 centers across the United States over a span of 17 weeks.

The trial results were compelling. Participants using the inhaled insulin regimen showed a marked improvement in their HbA1c levels. Specifically, 21 percent of the patients on inhaled insulin experienced an HbA1c improvement of more than 0.5 percent, compared to just 5 percent of those on standard care. Additionally, among those who started with an HbA1c level of 7 percent or higher, 21 percent of the inhaled insulin group managed to achieve the target HbA1c level of less than 7 percent, whereas none from the standard care group reached this goal.

An interesting finding emerged among participants who transitioned from an automated insulin delivery system to the inhaled insulin plus degludec regimen. In this subgroup, 19 percent achieved an HbA1c improvement greater than 0.5 percent. However, it is worth noting that 26 percent of the patients in the inhaled insulin group experienced a worsening of HbA1c levels by more than 0.5 percent, in contrast to only 3 percent in the standard care group.

Dr. Hirsch highlighted the broader implications of the INHALE-3 study, suggesting that the findings could significantly influence diabetes management strategies. "The results of this study are vital for healthcare providers and patients as they present an alternative method for insulin delivery," he stated. "These insights will help in making more informed clinical decisions and tailoring treatments to meet the specific needs of patients. This, in turn, can enhance adherence to treatment plans, boost patient satisfaction, and improve overall health outcomes."

The research underscores the potential for inhaled insulin to offer a viable and effective alternative to traditional insulin delivery methods, potentially transforming the approach to managing type 1 diabetes. By providing a different mode of administration, inhaled insulin could cater to patient preferences and improve the overall treatment experience, which is crucial for long-term disease management.

As the medical community continues to explore and validate new treatment options, studies like this one are essential in advancing our understanding and capabilities in diabetes care. The promising results of the INHALE-3 study suggest that inhaled insulin could become a valuable tool in the ongoing effort to optimize treatment strategies for type 1 diabetes patients.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!